Anavex Lf SC (AVXL) Stock Price, Quote & News

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-c...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 689 3939

Website: www.anavex.com

Address:

630 5th Avenue, 20th Floor, New York, United States

Georgejj Aug. 24 at 1:21 AM

$AVXL Could it be that Dr. Missling was fired for receiving at least one or maybe several offers to buy Anavex Life Sciences and turned this or these offers down without bringing the offers to the BOD for them to present the offers to the shareholders for a vote??? Good luck and GOD bless,

0 · Reply

Kb1123 Aug. 24 at 12:28 AM

$AVXL why anyone on this board still puts any value or truth to what Clint says is beyond me! Question: has anyone asked why they fired Dr.Jin the lead statistician who previously worked for the FDA?

1 · Reply

jcolespartan Aug. 23 at 9:35 PM

$AVXL

1 · Reply

AntonioChigurh Aug. 23 at 7:16 PM

$AVXL Bro, Tom Bishop can’t even UNMUTE himself on conference calls!!

0 · Reply

AntonioChigurh Aug. 23 at 7:14 PM

$AVXL Missling now playing 4D CHESS suing the company that turned him into a Multimillionaire!? What a sad piece of shit human being he is for stringing shareholders for more than a decade.

0 · Reply

TheLawman Aug. 23 at 6:40 PM

$AVXL I am awaiting word from Tom Bishop, of BI Research, on which slate of directors he prefers as Tom seems to have very good insight on this company.

1 · Reply

USAEquityResearch Aug. 23 at 5:24 PM

$AVXL 📊 USAEquityResearch ▲ 3.24 (+3.51%) Trend: Bullish 📈 RSI (14): 60.1 — strong momentum, approaching overbought MACD: bearish, below signal line Volume: below average 📌 Key Levels Resistance: 3.51 | Support: 2.49 20-MA: 3.10 | 50-MA: 2.77 💼 Fundamentals Mkt Cap: $300.34M FCF: $-39.04M (-0.42/sh) 📉 Options (exp 2026-09-18) ATM IV: 80.3% | Skew: -11.3% (call-heavy) P/C Ratio: 0.07 🐂 Bullish lean Max Pain: 3.00 Call wall: 4.00 | Put wall: 3.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/AVXL

0 · Reply

cy390 Aug. 23 at 4:03 PM

$AVXL The numbers were always clear: no clinical benefit was ever proven.

0 · Reply

cy390 Aug. 23 at 3:58 PM

$AVXL I, too, voted for more of the same. That's what we, at AVXL, do.

0 · Reply

zigsfrd Aug. 23 at 3:29 PM

$AVXL Despite my revulsion to doing so, I voted for the recommended nominees. PVG offers no science pathway just financial expertise to probably sell off assets without product developement. Eliminating Missling was key although not mentioned in Stockholder letter. There appears to be a narrowing of the focus on drug developement to only certain areas and I excuse the new CEO for now for lack of communication with all the work that was required to right this clusterf'k post Missling. I hope i dont end up eating crow ignoring my first impulse which was to wipe the board clean. If it doesn't work out... I like my crow medium rare.

2 · Reply

Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees

AVXL

Aug 17, 2026, 8:00 AM EDT - 6 days ago

Anavex Life Sciences Proxy statement: Proxy filing

Aug 17, 2026, 8:00 AM EDT - 6 days ago

Anavex Life Sciences Proxy statement: Proxy filing

Aug 11, 2026, 8:00 AM EDT - 12 days ago

Anavex Life Sciences Proxy statement: Proxy filing

Aug 11, 2026, 8:00 AM EDT - 12 days ago

Anavex Life Sciences Proxy statement: Proxy filing

Aug 3, 2026, 8:00 AM EDT - 20 days ago

Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

AVXL

Jul 31, 2026, 8:00 AM EDT - 23 days ago

Anavex Life Sciences Proxy statement: Proxy filing

Jul 30, 2026, 8:00 AM EDT - 24 days ago

Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

AVXL

Jul 24, 2026, 8:00 AM EDT - 4 weeks ago

Anavex Life Sciences Proxy statement: Proxy filing

May 22, 2026, 8:00 AM EDT - 3 months ago

Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

AVXL

2026-05-07T04:34:31.000Z - 3 months ago

Anavex Life Sciences names Terrie Kellmeyer interim CEO, succeeding Missling

AVXL

May 6, 2026, 7:00 AM EDT - 3 months ago

Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer

AVXL

Apr 14, 2026, 1:30 PM EDT - 4 months ago

Anavex Life Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 7:30 AM EDT - 4 months ago

Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease

AVXL

Apr 7, 2026, 7:30 AM EDT - 4 months ago

Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference

AVXL

Mar 30, 2026, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Provides Comprehensive Regulatory Update

AVXL

Mar 25, 2026, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease

AVXL

Mar 23, 2026, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease

AVXL

Mar 20, 2026, 7:30 AM EDT - 5 months ago

New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease

AVXL

Mar 17, 2026, 7:30 AM EDT - 5 months ago

Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference

AVXL

Mar 3, 2026, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

AVXL

Mar 2, 2026, 11:50 AM EST - 6 months ago

Anavex Life Sciences Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

AVXL

Feb 23, 2026, 7:30 AM EST - 6 months ago

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

AVXL

Feb 9, 2026, 8:30 AM EST - 6 months ago

Anavex Life Sciences Earnings Call Transcript: Q1 2026

Feb 9, 2026, 8:30 AM EST - 6 months ago

Anavex Life Sciences Earnings release: Q1 2026

Feb 9, 2026, 8:30 AM EST - 6 months ago

Anavex Life Sciences Quarterly report: Q1 2026

Feb 9, 2026, 7:30 AM EST - 6 months ago

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

AVXL

Feb 3, 2026, 7:30 AM EST - 7 months ago

Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

AVXL

Jan 14, 2026, 7:30 PM EST - 7 months ago

Anavex Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 AM EST - 7 months ago

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease

AVXL

Jan 8, 2026, 7:30 AM EST - 8 months ago

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

AVXL

Jan 6, 2026, 7:30 AM EST - 8 months ago

Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program

AVXL

Dec 18, 2025, 7:30 AM EST - 8 months ago

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

AVXL

Nov 26, 2025, 7:30 AM EST - 9 months ago

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

AVXL

Nov 25, 2025, 8:30 AM EST - 9 months ago

Anavex Life Sciences Earnings Call Transcript: Q4 2025

Nov 25, 2025, 8:30 AM EST - 9 months ago

Anavex Life Sciences Annual report: Q4 2025

Nov 25, 2025, 8:30 AM EST - 9 months ago

Anavex Life Sciences Earnings release: Q4 2025

Nov 25, 2025, 7:30 AM EST - 9 months ago

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

AVXL

Nov 19, 2025, 7:30 AM EST - 9 months ago

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

AVXL

Nov 18, 2025, 7:30 AM EST - 9 months ago

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

AVXL

Nov 14, 2025, 7:30 AM EST - 10 months ago

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

AVXL

Oct 29, 2025, 7:30 AM EDT - 10 months ago

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group

AVXL

Oct 10, 2025, 7:30 AM EDT - 11 months ago

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'

AVXL

Oct 2, 2025, 7:35 AM EDT - 11 months ago

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

AVXL

Oct 2, 2025, 7:30 AM EDT - 11 months ago

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

AVXL

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial

AVXL

Sep 9, 2025, 1:00 PM EDT - 1 year ago

Anavex Life Sciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial

AVXL

Sep 2, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

AVXL

Aug 26, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

AVXL

Aug 20, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease

AVXL

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q3 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Quarterly report: Q3 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings release: Q3 2025

Aug 12, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

AVXL

Aug 5, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

AVXL

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

AVXL

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Anavex Life Sciences Registration statement: Registration Filing

May 14, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

AVXL

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q2 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Quarterly report: Q2 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings release: Q2 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

AVXL

May 6, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

AVXL

May 1, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

AVXL

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

AVXL

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Anavex Life Sciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Anavex Life Sciences Proxy statement: Proxy Filing

Apr 23, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

AVXL

Apr 21, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

AVXL

Apr 7, 2025, 3:45 PM EDT - 1 year ago

Anavex Life Sciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 5, 2025, 11:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

AVXL

Georgejj Aug. 24 at 1:21 AM

0 · Reply

Kb1123 Aug. 24 at 12:28 AM

$AVXL why anyone on this board still puts any value or truth to what Clint says is beyond me! Question: has anyone asked why they fired Dr.Jin the lead statistician who previously worked for the FDA?

1 · Reply

jcolespartan Aug. 23 at 9:35 PM

$AVXL

1 · Reply

AntonioChigurh Aug. 23 at 7:16 PM

$AVXL Bro, Tom Bishop can’t even UNMUTE himself on conference calls!!

0 · Reply

AntonioChigurh Aug. 23 at 7:14 PM

$AVXL Missling now playing 4D CHESS suing the company that turned him into a Multimillionaire!? What a sad piece of shit human being he is for stringing shareholders for more than a decade.

0 · Reply

TheLawman Aug. 23 at 6:40 PM

$AVXL I am awaiting word from Tom Bishop, of BI Research, on which slate of directors he prefers as Tom seems to have very good insight on this company.

1 · Reply

USAEquityResearch Aug. 23 at 5:24 PM

0 · Reply

cy390 Aug. 23 at 4:03 PM

$AVXL The numbers were always clear: no clinical benefit was ever proven.

0 · Reply

cy390 Aug. 23 at 3:58 PM

$AVXL I, too, voted for more of the same. That's what we, at AVXL, do.

0 · Reply

zigsfrd Aug. 23 at 3:29 PM

2 · Reply

keyeaster Aug. 23 at 1:42 PM

$AVXL The Oracle said; "Buy when others sre fearful".

3 · Reply

WestCoastRules Aug. 23 at 11:28 AM

$AVXL I think she will speak either next week or the following. They have to speak and show their plan moving forward if they want the votes to go the right way. I suspect next week for a press release but gave myself some wiggle room. The sooner we get it the more votes for the board. The only one I am not voting for is Ma.

0 · Reply

Tunken Aug. 23 at 11:24 AM

$AVXL Clint say we will hear something soon.

2 · Reply

Woundntyouliketoknow Aug. 23 at 10:36 AM

$AVXL - Still no word from the new CEO. Is she able to speak? All we have seen so far is how qualified she is due to her great background. She is a no opp. She is totaly incompetent. Still no new phase 3 AD trial or Rett trial. It is criminal that 30+ people are still collecting a paycheck for doing nothing.

0 · Reply

JuggernautRaider Aug. 23 at 4:17 AM

$AVXL hard to see a path forward for ole Avanex

0 · Reply

Minnesotastockdude Aug. 23 at 4:08 AM

$AVXL Hello to everyone. What a sad story this has become. I sold everything and moved on after the latest rejection. It’s been refreshing and empowering to not live with this never ending, stressful string along. I cannot believe missling is actually suing the company. What an absolute steaming dump of poo and pathetic excuse for a human being. He led the company astray for over a decade, made millions in the process, managed to mess up the trail designs for both rett and Alzheimer’s and failed miserably, not getting a single thing commercialized. And after the board finally dumps him, he has the arrogance to sue them. Truly the scum of the earth I have lost all hope that this drug will ever see the light of day. I sincerely hope I’m wrong and that the ship is eventually turned around I would buy back in if they get to a place of competent leadership with a properly designed trial, given the incredible efficacy shown in previous trials.

1 · Reply

J903625 Aug. 22 at 5:05 PM

$AVXL losing watchers every day. People are jumping ship. Too much chaos and unaccountability or effective plan of action.

0 · Reply

Logic102 Aug. 22 at 2:50 PM

$AVXL With Chaos in the FDA and an anti-science bias, I can't say that RFK's anti-amyloid plaque rhetoric is gaining any momentum. The anti-science, anti-vaccination and anti-BP rhetoric seems to be overshadowing the "let's innovate and get novel drugs to the Market quickly" rhetoric. Can't say that I have any confidence in this Administration regarding healthcare or CNS drug development. They have two dueling priorities: one is promoting Conspiracy Theories and demonizing big pharma and the other is supposedly getting drugs and new treatments to Market much faster. It appears that #1 is winning.

0 · Reply

Georgejj Aug. 22 at 2:23 PM

$AVXL Taking Vitamin D Daily Was Associated With Better Cognitive Performance in Those at Risk of Alzheimer's and Dementia Discover how people with sleep disturbance and mild cognitive impairment who took 5,000 IU of vitamin D daily performed better on memory and thinking assessments. If you plan on taking 5000 IUs of vitamin D3, then consult your physician and don’t forget to take 100 mcg of vitamin K2 as well. https://www.discovermagazine.com/taking-vitamin-d-daily-was-associated-with-better-cognitive-performance-in-those-at-risk-of-alzheimer-s-and-dementia-49571 Good luck and GOD bless,

2 · Reply

Logic102 Aug. 22 at 2:12 PM

$AVXL The tragedy of Anavex is wasted time. Good management would have learned from the two failed P3 trials for Rhett and AD as neither trial was a total failure, they just had trial design flaws and some unavoidable issues due to Covid 19 for the AD trial. The CEO would have "shaken the dust from his sandals," regrouped, dilution be damned, and we would have two products being sold today. Now, with this dueling Board situation and Missling lawsuit BS, the company is wasting more and more time.

2 · Reply

LongstreetBio Aug. 22 at 12:39 PM

$AVXL I find myself disappointed here as are most others. Many seem to have sold and moved on. I have reduced my holdings from 33k shares to 4k shares. While taking a loss burns, the tax loss allowed my reallocation of capital to spur new growth elsewhere. I'm holding on to the 4k because I believe "if the drug is good", it will find it's way to market, despite an inept BOD. I don't know who I should vote for, but for now, I am sticking with the losers that got us here. Don't ask me why. I suppose I think they are the lesser of the two evils.

2 · Reply

Tunken Aug. 22 at 12:03 PM

$AVXL I find it interesting that people would listen to Clint. Very little reliable information has he revealed in the past.

2 · Reply

Market Cap	300.34M
Revenue (ttm)	0.00
Net Income (ttm)	-46.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	480,700
Avg Vol	1,159,552
Day's Range	N/A - N/A
Shares Out	92.70M
Stochastic %K	31%
Beta	1.15
Analysts	Sell
Price Target	$20.00